Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
April 30 2019 - 7:30AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty
pharmaceutical company focused on the development and
commercialization of intravenous (IV) tramadol, today announced
that Dr. Thomas G. Moore has been appointed to its Board of
Directors.
“Tom’s breadth and depth of operational and commercial
experience, which includes leadership in the acute care
pharmaceutical business, will be a significant asset to Avenue,”
said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman. “Tom is
well suited to help Avenue execute on its mission of bringing IV
tramadol to the U.S. market, and we are excited to add him to our
Board.”
“Avenue is nearing Phase 3 completion for IV tramadol, which
could become an important addition in acute pain management in the
U.S.,” said Dr. Moore. “I am delighted to lend my expertise to the
organization and join the Board of Directors to help unlock value
from this program.”
Thomas G. Moore is a retired pharmaceutical industry executive
with more than 35 years of strategic and operational experience
including extensive knowledge of the acute care pharmaceutical
business, strategic planning and business development based on his
work at major public companies. Dr. Moore served as President of
Hospira USA from 2009 until his retirement in 2014. He was
President of Global Pharmaceuticals for Hospira Worldwide, Inc.
from 2007 to 2009, and served as Vice President and General Manager
of Specialty Pharmaceuticals for Hospira, Inc. from 2003 to 2007.
Dr. Moore sits on the Board of Directors of Akorn Pharmaceuticals
and the Board of Trustees for Rosalind Franklin University of
Medicine and Science. Dr. Moore received his undergraduate degree
from Loyola Marymount University, Los Angeles, and his Doctor of
Pharmacy from the University of Southern California.
About Avenue TherapeuticsAvenue is a specialty
pharmaceutical company focused on the development and
commercialization of intravenous (IV) tramadol for the management
of moderate to moderately severe postoperative pain. IV tramadol
may fill a gap in the acute pain market between IV
acetaminophen/NSAIDs and IV conventional narcotics. Avenue is
currently evaluating IV tramadol in a pivotal Phase 3 program for
the management of postoperative pain. Avenue is headquartered in
New York City and was founded by Fortress Biotech, Inc. (NASDAQ:
FBIO). For more information, visit
www.avenuetx.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; risks relating to the results of research and development
activities; risks relating to the timing of starting and completing
clinical trials; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; our dependence on
third-party suppliers; our ability to attract, integrate and retain
key personnel; the early stage of products under development; our
need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as
other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contacts: Jaclyn Jaffe and William Begien,
Investor RelationsAvenue Therapeutics, Inc.(781) 652‐4500
ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024